HiberCell Raises $60.75M in Series A Funding

HiberCell logoHiberCell, a New York City-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, raised $60.75m in Series A funding.

The round was led by Arch Venture Partners, with participation from Hillhouse Capital, 6 Dimensions Capital, Celgene Corporation, the NYC Life Sciences Fund and undisclosed institutional investors, family offices and private individuals.

HiberCell is a biotechnology company exclusively focused on developing therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers.

The team consists of cancer scientists, venture capitalists and drug developers who are leaders within their respective fields. At launch, Alan Rigby, Ph.D., will lead the company as president and chief scientific officer. Ari Nowacek, Ph.D., M.D., principal at ARCH Venture Partners, will serve as vice president of operations and business development, and Mark Mulvihill, Ph.D., will serve as vice president of chemistry and drug discovery.

The Board of Directors includes:
– Steven Gillis, Ph.D., chairman of the board at HiberCell, managing director at ARCH Venture Partners
– Alan Rigby, Ph.D., president and chief scientific officer at HiberCell
– Ari Nowacek, M.D., Ph.D., principal at ARCH Venture Partners & vice president, operations and business development at HiberCell
– Kevin Heyeck, Ph.D., venture partner at 6 Dimensions Capital
– Michael Yi, Ph.D., partner at Hillhouse Capital

The Scientific Advisory Board includes:
– Julio Aguirre-Ghiso, Ph.D., director of Solid Tumor and Metastasis Research, director of Head and Neck Cancer Basic Research, co-leader of the Cancer Mechanisms Program and professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine
– Christoph Klein, M.D., Ph.D., head of the Department of Experimental Medicine and Therapy Research at the University of Regensburg, head of Personalized Tumor Therapy, a division of Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
– Ruggero De Maria, M.D., professor and director of the Institute of General Pathology at the Catholic University of Rome, president of the Italian Institute for Genomic Medicine in Turin, Italy and president of the Italian Alliance Against Cancer network.



Join the discussion